Loading…
Based on limited metadata, this Warning Letter was issued to 8046255 Canada Inc. (doing business as Viatrexx), a company involved in drug manufacturing or distribution. Without access to the full letter text or specific subject line, the exact nature of the violations cannot be determined from the available information. The FDA's drug product division issued this enforcement action in June 2020, indicating the violations likely relate to drug manufacturing, quality control, or regulatory compliance requirements. Additional details would be needed to specify the particular violations cited.